Skip to NavigationSkip to content

Sanofi's Soliqua proves superior to GLP-1 RA therapies in reducing blood sugar levels

Published on 10/06/19 at 12:25pm

Sanofi has stepped up at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco, revealing new data which indicate that Soliqua (insulin glargine and lixisenatide) met its primary endpoint in the treatment of type 2 diabetes patients.

According to the findings, Soliqua demonstrated a “statistically superior reduction of average blood sugar level (HbA1C)” after 26 weeks of treatment compared to continued GLP-1 RA therapy when receiving Sanofi’s drug once weekly or daily.

Specifically, it was found that a higher proportion of patients switching to Soliqua reported HbA1C levels of lower than the ADA’s recommendation of 7%, as well as without documented symptomatic hypoglycaemia, compared to continued GLP-1 RA therapy.  

"We are committed to providing people living with diabetes a broad range of options that can help support personalised care," commented Rachele Berria, Global Head of Diabetes Medical Affairs at Sanofi. "As the first comparison between Soliqua and both daily and weekly GLP-1 RA treatments, this study provides physicians with new data that they could use when considering Soliqua as a part of a personalised treatment plan."

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches